Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, April 25, 2024 | Back issues
Courthouse News Service Courthouse News Service

Drug Antitrust

A federal antitrust complaint claims Bausch Health Cos., Salix Pharmaceuticals, et al. increased prices for the diabetes prescription drug Glumetza by up to 50 times the fair market price: as high as $3,000 for a month’s supply.

SAN FRANCISCO — A federal antitrust complaint claims Bausch Health Cos., Salix Pharmaceuticals and others increased prices for the diabetes prescription drug Glumetza by up to 50 times the fair market price: as high as $3,000 for a month’s supply.

Categories / Business, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...